Results 41 to 50 of about 231,777 (344)

Therapeutic potential of TRPM8 antagonists in prostate cancer

Scientific Reports, 2021
Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear.
Marzia Di Donato, Carmine Ostacolo, Pia Giovannelli, Veronica Di Sarno, Isabel M. Gomez Monterrey, Pietro Campiglia, Antimo Migliaccio, Alessia Bertamino, Gabriella Castoria   +8 more
doaj   +1 more source

Androgen receptor polymorphisms and testicular cancer risk [PDF]

, 2015
Testicular cancer (TC) is currently the most common malignant solid tumour in Caucasian males aged 15-39 years. Epidemiological evidence suggests that its onset may be due to an imbalance in the action of steroidal sex hormones and their receptors.
CARLINI, TANIA, F. Rizzo, GANDINI, Loredana, GIANNANDREA, FABRIZIO, GRASSETTI, Daniele, LENZI, Andrea, LOMBARDO, Francesco, MASCIANDARO, PAOLA, PAOLI, Donatella, V. Figura   +9 more
core   +1 more source

The epigenetic function of androgen receptor in prostate cancer progression

Frontiers in Cell and Developmental Biology, 2023
Androgen and androgen deprivation (castration) therapies, including androgen receptor antagonists, are clinically used to treat patients with prostate cancer.
Takahiro Sawada, Takahiro Sawada, Yoshiaki Kanemoto, Yoshiaki Kanemoto, Tomohiro Kurokawa, Tomohiro Kurokawa, Tomohiro Kurokawa, Shigeaki Kato, Shigeaki Kato, Shigeaki Kato   +9 more
doaj   +1 more source

Androgen-independent events in penile development in humans and animals. [PDF]

, 2020
The common view on penile development is that it is androgen-dependent, based first and foremost on the fact that the genital tubercle forms a penis in males and a clitoris in females.
Baskin, Laurence, Cao, Mei, Cooke, Paul S, Cunha, Gerald R, Glickman, Steve, Liu, Ge, Sinclair, Adriane   +6 more
core   +1 more source

Effect of antiandrogen flutamide on measures of hepatic regeneration in rats [PDF]

, 1989
Male rat liver undergoes a process of demasculinization during hepatic regeneration following partial hepatectomy. The possibility that antiandrogens might potentiate this demasculinization process and in so doing augment the hepatic regenerative ...
A Francavilla, A Mode, A Schleusener, AE Pegg, AJ Syms, B Katchen, CL Mendenhall, CW Bardin, D Kahn, DM Cohen, E Bresnidk, E Mezey, E Mezey, E Mezey, EM Higgins, ER Lax, F Neumann, J Simard, J Terblanche, JA Gustafsson, JA Gustafsson, JA McGowan, JH Clark, JM Kissane, JP Blondeau, KE Crow, LE Porter, M Kayfman, M Sarff, MF Zuretti, OH Lowry, PK Eagon, PK Eagon, PK Eagon, R Neri, W Welshons, WJ King   +36 more
core   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source

Androgen receptors as a prognostic and predictive factor in breast cancer.

Folia Histochemica et Cytobiologica, 2008
Many theoretical and experimental models indicate that androgen receptors can play an important role as prognostic factors in breast cancer. The aim of this study was to evaluate the correlations between the presence of androgen receptors on cancer cells
Jerzy Rudnicki, Piotr Zukrowski, Zygmunt Grzebieniak, Michał Jeleń, Anil K Agrawal, Ewa Nienartowicz   +5 more
doaj   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation

Neoplasia: An International Journal for Oncology Research, 2018
Current treatment strategies provide minimal results for patients with castration-resistant prostate cancer (CRPC). Attempts to target the androgen receptor have shown promise, but resistance ultimately develops, often due to androgen receptor ...
Nicholas E. Brown, Andrew M. Paluch, Madison A. Nashu, Kakajan Komurov, Susan E. Waltz   +4 more
doaj   +1 more source

SHH-N non-canonically sustains androgen receptor activity in androgen-independent prostate cancer cells

Scientific Reports, 2021
Prostate cancer is the second most frequent cancer diagnosed in men worldwide. Localized disease can be successfully treated, but advanced cases are more problematic. After initial effectiveness of androgen deprivation therapy, resistance quickly occurs.
Diana Trnski, Maja Sabol, Sanja Tomić, Ivan Štefanac, Milanka Mrčela, Vesna Musani, Nikolina Rinčić, Matea Kurtović, Tina Petrić, Sonja Levanat, Petar Ozretić   +10 more
doaj   +1 more source